ASCO 2020

par Bartsch, Rupert, Dieras, Veronique, Cortes, Javier, Müller, Volkmar, Ruhstaller, Thomas
Publié dans Breast Care (Basel) (2020)

Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8–11, 2020

par Müller, Volkmar, Dieras, Veronique, Cardoso, Fatima, Cameron, David, Cortes, Javier
Publié dans Breast Care (Basel) (2021)

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic H...

par Paracha, Noman, Reyes, Adriana, Diéras, Véronique, Krop, Ian, Pivot, Xavier, Urruticoechea, Ander
Publié dans Breast Cancer Res Treat (2020)

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib

par Zheng, Jenny, Yu, Yanke, Durairaj, Chandrasekar, Diéras, Véronique, Finn, Richard S., Wang, Diane D.
Publié dans Target Oncol (2020)

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall...

par Diéras, Véronique, Miles, David, Verma, Sunil, Pegram, Mark, Welslau, Manfred, Baselga, José, Krop, Ian E, Blackwell, Kim, Hoersch, Silke, Xu, Jin, Green, Marjorie, Gianni, Luca
Publié dans Lancet Oncol (2017)

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

par Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Publié dans Br J Clin Pharmacol (2016)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

par Diéras, Véronique, Harbeck, Nadia, Joy, Anil Abraham, Gelmon, Karen, Ettl, Johannes, Verma, Sunil, Lu, Dongrui R., Gauthier, Eric, Schnell, Patrick, Mori, Ave, Rugo, Hope S., Finn, Richard S.
Publié dans Oncologist (2019)

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

par Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth
Publié dans Br J Cancer (2017)

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated...

par Sabatier, Renaud, Diéras, Véronique, Pivot, Xavier, Brain, Etienne, Roché, Henri, Extra, Jean-Marc, Monneur, Audrey, Provansal, Magali, Tarpin, Carole, Bertucci, François, Viens, Patrice, Zemmour, Christophe, Gonçalves, Anthony
Publié dans Cancer Res Treat (2018)

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

par Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, Cortés, Javier
Publié dans Future Oncol (2019)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

par Diéras, Véronique, Bachelot, Thomas, Campone, Mario, Isambert, Nicolas, Joly, Florence, Le Tourneau, Christophe, Cassier, Philippe, Bompas, Emmanuelle, Fumoleau, Pierre, Noal, Sabine, Orsini, Christine, Jimenez, Marta, Imbs, Diane Charlotte, Chatelut, Etienne
Publié dans Oncol Ther (2016)

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

par Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Publié 2012

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

par Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Publié 2012

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

par Verma, Sunil, Miles, David, Gianni, Luca, Krop, Ian E., Welslau, Manfred, Baselga, José, Pegram, Mark, Oh, Do-Youn, Diéras, Véronique, Guardino, Ellie, Fang, Liang, Lu, Michael W., Olsen, Steven, Blackwell, Kim
Publié dans N Engl J Med (2012)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients

par Jobard, Elodie, Trédan, Olivier, Bachelot, Thomas, Vigneron, Arnaud M., Aït-Oukhatar, Céline Mahier, Arnedos, Monica, Rios, Maria, Bonneterre, Jacques, Diéras, Véronique, Jimenez, Marta, Merlin, Jean-Louis, Campone, Mario, Elena-Herrmann, Bénédicte
Publié dans Oncotarget (2017)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

par Diéras, Véronique, Rugo, Hope S, Schnell, Patrick, Gelmon, Karen, Cristofanilli, Massimo, Loi, Sherene, Colleoni, Marco, Lu, Dongrui R, Mori, Ave, Gauthier, Eric, Huang Bartlett, Cynthia, Slamon, Dennis J, Turner, Nicholas C, Finn, Richard S
Publié dans J Natl Cancer Inst (2018)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breas...

par Finn, Richard S., Rugo, Hope S., Gelmon, Karen A., Cristofanilli, Massimo, Colleoni, Marco, Loi, Sherene, Schnell, Patrick, Lu, Dongrui R., Theall, Kathy Puyana, Mori, Ave, Gauthier, Eric, Bananis, Eustratios, Turner, Nicholas C., Diéras, Véronique
Publié dans Oncologist (2021)

MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

par Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Publié dans Clin Cancer Res (2017)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

par Hatem, Rana, Botty, Rania El, Chateau-Joubert, Sophie, Servely, Jean-Luc, Labiod, Dalila, de Plater, Ludmilla, Assayag, Franck, Coussy, Florence, Callens, Céline, Vacher, Sophie, Reyal, Fabien, Cosulich, Sabina, Diéras, Véronique, Bièche, Ivan, Marangoni, Elisabetta
Publié dans Oncotarget (2016)

NT-23 PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

par Kerklaan, Bojana Milojkovic, Jager, Agnes, Aftimos, Philippe, Dieras, Veronique, Altintas, Sevilay, Anders, Carey, Arnedos, Monica, Gelderblom, Hans, Soetekouw, Patricia, Gladdines, Werner, Gaillard, Pieter, de Sousa, Carlos, Awada, Ahmad, Schellens, Jan, van Linde, Myra, Brandsma, Dieta
Publié 2014